Abstract
A new composition of ferroceron with improved organoleptic properties has been scientifically substantiated and proposed, which makes it possible to expand the scope of application of ferroceron in children with iron deficiency anemia, regardless of age. For the first time in young children with iron deficiency anemia, a comparative study of the therapeutic efficacy of ferroceron in rosehip syrup was carried out. At the same time, not only immediate but also long-term results of treatment were analyzed. The newly created composition of ferroceron in rosehip syrup, used as an iron-containing drug in the treatment of iron deficiency anemia in young children, turned out to be a highly effective agent without side properties. A comparative assessment of the antianemic effect of a combination of ferroceron and other iron-containing drugs, often used in children’s practice, is given, which gave reason to recommend ferroceron with rosehip syrup as an antianemic drug that has an effect on the processes of hemoglobin synthesis and an erythrostimulating effect. The predominant both direct and long-term effect of treatment of children with ferrocerone in rosehip syrup was revealed, which determined the created composition to be considered the drug of choice in the treatment of young children with iron deficiency anemia, an etiopathogenetic agent.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call